Trial · NCT03170271
Adverse events80
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
61 to 80 of 80
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Acute kidney injury | Renal and urinary disorders | Benralizumab | 0 | 427 | 0 |
| serious | Acute kidney injury | Renal and urinary disorders | Placebo | 1 | 229 | 1 |
| serious | Nephrolithiasis | Renal and urinary disorders | Benralizumab | 1 | 427 | 1 |
| serious | Nephrolithiasis | Renal and urinary disorders | Placebo | 0 | 229 | 0 |
| serious | Renal failure | Renal and urinary disorders | Benralizumab | 1 | 427 | 1 |
| serious | Renal failure | Renal and urinary disorders | Placebo | 0 | 229 | 0 |
| serious | Female genital tract fistula | Reproductive system and breast disorders | Benralizumab | 1 | 427 | 1 |
| serious | Female genital tract fistula | Reproductive system and breast disorders | Placebo | 0 | 229 | 0 |
| serious | Asthma | Respiratory, thoracic and mediastinal disorders | Benralizumab | 9 | 427 | 10 |
| serious | Asthma | Respiratory, thoracic and mediastinal disorders | Placebo | 9 | 229 | 11 |
| serious | Epistaxis | Respiratory, thoracic and mediastinal disorders | Benralizumab | 0 | 427 | 0 |
| serious | Epistaxis | Respiratory, thoracic and mediastinal disorders | Placebo | 1 | 229 | 1 |
| serious | Pneumonitis | Respiratory, thoracic and mediastinal disorders | Benralizumab | 1 | 427 | 1 |
| serious | Pneumonitis | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 229 | 0 |
| serious | Pneumothorax | Respiratory, thoracic and mediastinal disorders | Benralizumab | 0 | 427 | 0 |
| serious | Pneumothorax | Respiratory, thoracic and mediastinal disorders | Placebo | 1 | 229 | 1 |
| serious | Respiratory failure | Respiratory, thoracic and mediastinal disorders | Benralizumab | 0 | 427 | 0 |
| serious | Respiratory failure | Respiratory, thoracic and mediastinal disorders | Placebo | 2 | 229 | 2 |
| serious | Urticaria | Skin and subcutaneous tissue disorders | Benralizumab | 1 | 427 | 1 |
| serious | Urticaria | Skin and subcutaneous tissue disorders | Placebo | 0 | 229 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03170271/events?page=4